ArticleData in brief2019
Data describing effects of perinatal exposure to bisphenol S on a peripubertal estrogen challenge in intact female CD-1 mice.
Article in Data in brief, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bisphenol S (BPS) is an analogue of bisphenol A (BPA), used in consumer products including food packaging and thermal paper. Like BPA, BPS is an estrogen receptor agonist and exposures during perinatal development have been shown to alter growth and morphology of the mouse female mammary gland prior to puberty and in adulthood. Reported here are data describing the effect of exposure to low doses of BPS (2, 200 or 2000 μg/kg/day) during perinatal development on morphology and gene expression in the mammary gland of female CD-1 mice, with or without an additional estrogen exposure (1 μg/kg/day ethinyl estradiol) during the peripubertal period. Additional data document other estrogen-sensitive outcomes including timing of vaginal opening and uterine weight. The data suggest that low doses of BPS induce modest changes in the mammary gland at puberty, but do not appear to sensitize the female to an estrogenic challenge administered during the peripubertal period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.